retatrutide clinical trial results retatrutide Eli Lilly and Company's triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C Retatrutide Achieves Up to 30.3%
Pay in 4 interest-free payments of $5.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17




























